Product concentration
Nearly all revenue comes from one therapy platform, so any slowdown in adoption or product issues would affect results materially.
- Scope
- Sales of Inspire system accounted for substantially all revenue
- Materiality
- high
Inspire Medical Systems, Inc.
Inspire Medical Systems develops and commercializes a minimally invasive neurostimulation therapy for obstructive sleep apnea. Its proprietary Inspire system senses breathing and delivers mild hypoglossal nerve stimulation to keep the airway open, and it is sold primarily to hospitals and ambulatory surgery centers in the U.S. with additional international distribution.
7,1 %
85,4 %
15,9 %
+13,6 %
6.08
4.56
| % | |
|---|---|
| Inspire therapy systems | 95% Implantable neurostimulation systems used to treat moderate to severe OSA. |
| Next-generation Inspire V | 3% The newer platform launched in the U.S. to expand adoption and upgrade the installed base. |
| International distribution sales | 2% Sales through distributors in selected Asia-Pacific markets and other non-U.S. countries. |
The company sells to hospitals and ambulatory surgery centers, which are the purchasing entities for the procedure,...
- Hospitals and ambulatory surgery centersprimary
Primary purchasing customers that acquire the Inspire system for implantation procedures and need reimbursement support.
- ENT physicians and sleep centersprimary
Clinical referral and procedure-driving users who identify eligible OSA patients and influence adoption.
- Commercial payors and Medicare beneficiariesprimary
Patients covered by insurers and Medicare who need positive coverage policies for treatment access.
- International distributorssecondary
Channel partners in Japan, Singapore, Hong Kong, Thailand, and other select markets that sell and promote the therapy locally.
- Veterans Health Administrationsecondary
Government healthcare channel that purchases under contract for eligible patients.
Revenue is heavily concentrated in the United States, which represented 95.6% of 2025 revenue, while all other...
- •United States is the core market and the main revenue driver
- •Select European markets are served through direct sales
- •Japan is an approved market and an important international foothold
- •Singapore, Hong Kong, and Thailand are served through distributors
- •International growth depends on reimbursement and regulatory access
The company is focused on expanding adoption of Inspire therapy through physician education, direct-to-consumer...
01
Scale Inspire V adoptionshort-term
A newer platform can refresh demand, support upgrades, and improve the product's competitive position.
02
Expand reimbursement accessshort-term
Coverage policies are essential because treatment uptake depends on payor approval and patient affordability.
03
Increase patient and physician awarenessmedium-term
The business relies on referral-driven adoption and patient activation for procedure growth.
04
Expand international marketsmedium-term
Non-U.S. markets are still small but offer long runway if approvals and reimbursement improve.
The company is highly dependent on a single product franchise, so adoption, reimbursement, and competitive pressure...
Reimbursement and coverage risk
The therapy depends on third-party payor approval, prior authorization, and coverage policy maintenance.
- Scope
- Commercial insurers, Medicare, Medicare Advantage, and government programs
- Materiality
- high
Cybersecurity and IT disruption
Core functions such as manufacturing, distribution, and patient data handling rely on IT systems and third parties.
- Scope
- Sensitive patient and employee information, supply chain, order processing
- Materiality
- medium
Competitive substitution
Alternative OSA treatments, including GLP-1 drugs and competing neurostimulation devices, may divert patients or physicians.
- Scope
- Zepbound, Apnimed, Nyxoah, LivaNova
- Materiality
- medium
Sales force and capacity constraints
Growth depends on a large direct sales organization and enough trained surgeons to perform procedures.
- Scope
- ENT surgeon capacity constraints and direct sales execution
- Materiality
- medium
International regulatory and foreign exchange risk
Non-U.S. expansion requires approvals, local compliance, and exposure to currency and trade issues.
- Scope
- Europe and Asia-Pacific markets
- Materiality
- medium
Revenue recognition timing
Quarterly comparability and reported growth rates
Inventory and manufacturing-related estimates
Cost of goods sold and gross margin
Share-based compensation and tax on net share settlements
Operating expenses, equity, and cash flow
Capitalized equipment and tooling for Inspire V
Balance sheet and future cost structure
InspireMD, Inc.
NSPR · Surgical & Medical Instruments & Apparatus
INSPIRE VETERINARY PARTNERS, INC.
IVPR · Agricultural Services
InfuSystem Holdings, Inc
INFU · Surgical & Medical Instruments & Apparatus
Ispire Technology Inc.
ISPR · Cigarettes
Medicale Corp.
MCLE · Services-Health Services
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
: 28.4.2026